Eledon Pharmaceuticals, Inc. — Director's Dealing 2021

Mar 19, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Eledon Pharmaceuticals, Inc. (ELDN)
CIK: 0001404281
Period of Report: 2021-03-15

Reporting Person: Little Paul Sean (CHIEF FINANCIAL OFFICER)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$13.94	2031-03-15	Common Stock (160000)		Direct

Footnotes

F1: This option represents a right to purchase up to 160,000 shares of Common Stock, which option vests with respect to 40,000 shares on March 15, 2022, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending March 15, 2025.